A vaccine against EBV which prevents primary EBV infection should be able to control both BL and NPC.
Such a vaccine must be given early in life. Such a vaccine would also be useful in seronegative organ transplant recipients and those developing severe IM, such as the male offspring of X-linked proliferative syndrome carriers.
The vaccine should not preferably be a subunit vaccine since there is a danger that a live vaccine may still have tumorigenic properties.
The antigen chosen for vaccine development is the MA antigen gp 340/220 as antibodies against this antigen are virus neutralizing.
This vaccine is being tried in Africa.